由威爾士大學(xué)醫(yī)學(xué)院病理科D·溫福德-托馬斯博士建系，取樣于35歲正常女性甲狀腺濾泡上皮，SV40永生化處理后并保留了甲狀腺上皮細(xì)胞的幾種不同的功能，經(jīng)無支原體/STR鑒定入庫。

組織來源：甲狀腺，甲狀腺濾泡上皮細(xì)胞 

形態(tài)：上皮細(xì)胞樣，貼壁生長(zhǎng)

培養(yǎng)基配方：

90%1640基礎(chǔ)（MD0200)+10%FBS（SD0200)+ 2mM谷氨酰胺(SD0007)+1%GA(SD0038)

完全培養(yǎng)基鏈接：1640完全培養(yǎng)基（MD0228）

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

凍存條件：基礎(chǔ)培養(yǎng)基+5%DMSO+20%FBS（SD0200)

完全凍存液：免程序降溫細(xì)胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690

Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

Clin. Cancer Res. 17:7248-7264(2011)

PubMed=22087789; DOI=10.1186/1755-8166-4-26

Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.

Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.

Mol. Cytogenet. 4:26-26(2011)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953

Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Clin. Cancer Res. 25:3141-3151(2019)

LncRNA GLTC targets LDHA for succinylation and enzyme activity to promote differentiated thyroid cancer progression and radioiodine resistance ，DOI: https://doi.org/10.21203/rs.3.rs-1949475/v1

LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer；Cell Death & Differentiation volume 30, pages1517–1532 (2023)